Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leukemia
Argos Therapeutics reports dosing is initiated in phase I/II trial of AGS-005 in leukemia
February 27th, 2007
Argos Therapeutics announced that dosing has been initiated in a phase I/II clinical trial to test the activity and safety of AGS-005 in B-cell chronic lymphocytic leukemia (CLL). GS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells. "B-cell chronic lymphocytic leukemia is the most common adult leukemia in the Western hemisphere, yet there is no broadly applicable standard treatment with the promise to cure for this condition. Therefore, it is important to evaluate new treatment modalities...
Source: Cancer Weekly (2007-02-27)
|
